Press Release: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 6-9 January 2014

Following an in-depth review of the medicine, the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) recommended in January 2014 that Protelos/Osseor should no longer be used to treat osteoporosis

The PRAC recommendation will now be sent to the Agency’s Committee for Medicinal Products for Human Use (CHMP), which is expected to issue the Agency’s final opinion at its meeting of 20 to 23 January 2014.